期刊文献+

过氧化物酶体增殖物激活受体激动剂研究进展 被引量:1

下载PDF
导出
摘要 2型糖尿病(T2DM)是主要心血管危险因素之一。70%以上T2DM患者死于心血管并发症,T2DM已被列为冠心病(CHD)的等危症,控制血糖水平是预防T2DM患者心血管并发症的重要手段,除此之外,还应干预高血压、血脂异常、腹型肥胖、代谢综合征等。STENO-2研究发现,综合干预T2DM患者的多种心血管危险因素可显著改善患者预后。因此,国内外学者努力开发可控制心血管多重危险因素的降糖新药。
出处 《中西医结合心脑血管病杂志》 2015年第7期911-913,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献31

  • 1Plutzky J. Macrovascular effects and safety issues of therapies for type 2 diabetes[J]. Am J Cardiol, 2011, 108(3 Suppl) : 25B - 32B.
  • 2Gaede P, Lund - Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008, 358(6) :580- 591.
  • 3HiukkaA,Maranghi M, Matikainen N, etal. PPAR alpha:An emerging therapeutic target in diabetic microvascular damage [J]. Nature Reviews Endocrinology, 2010, 6(8) : 454- 463.
  • 4van BM, van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease[J]. Expert Opin Ther Targets, 2010, 14(10) : 1029- 1045.
  • 5Rubins H, Davenport J. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial(VA HIT) [J]. Circula tion, 2001, 103(23) :2828 - 2833.
  • 6Tenenbaum A, Morro M, Fisman EZ, et al. Bezafibrate for the secondary prevention al myocardial infarction in patients with the metabolic syndrome[J]. Arch Intern Med, 2005, 165 (10) :1154 - 1160.
  • 7Goldenberg I, Goldbourt U, Boyko V, et al. Relation between on - treatment increments in serum high - density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease(from the Bezafibrate Infarction Prevention trial) [J]. Am J Cardiol, 2006, 97(4) : 466- 471.
  • 8Burgess DC, Hunt D, Li L, et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: An analysis from the Fenofibrate Intervention and E- vent Lowering in Diabetes(FIELD) study[J]. Eur Heart J, 2010, 31(1): 92-99.
  • 9Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovas- cular disease prevention, the ACCORD Lipid perspective[J]. Curt Opin Lipidol, 2011, 22(1) : 55 - 61.
  • 10Caldwell SH, Argo CK, AI- Osaimi AM. Therapy of NAFLD: in- sulin Sensitizing Agents [J]. J Clin Gastroenterol, 2006, 40 (Suppl) :61 - 66.

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部